EarningsTime

📊 EARNINGS WEEK | NOV 2–6 Wall Street faces another packed earnings week, with Apple, AMD, Palantir, Shopify, Uber, Qualcomm and MercadoLibre among the biggest names reporting. AI spending, cloud growth, consumer demand and forward guidance will be key themes to watch. From mega-cap tech to retail favorites, our 2-slide calendar covers the most anticipated reports before the open and after the close. Here's what's coming next week. 👇 $AAPL $AMD $PLTR $SHOP $UBER $MELI $QCOM $ARM $APP $DDOG $NET $ABNB $CRCL $IONQ $SOUN $OKLO $ROKU $DUOL $CAVA $AFRM

📉 OCT 30 | MARKET CLOSE Nasdaq -2.9% | S&P 500 -1.8% | Dow -1.1% $INTC plunged ~29% as AI spending fears hit tech. $XOM and $CVX gained. October: Nasdaq ~-5%, S&P 500 ~-1%, Dow ~+2%. A brutal month-end for tech as Wall Street questions AI returns.

Big Tech is on track to spend ~$730B in capital expenditures in 2026, much of it driven by AI. Amazon alone expects $220B in CapEx, while its trailing free cash flow has fallen to -$42.4B. AI demand is booming. Wall Street wants to see the returns.

🚨 CRYPTO STOCKS UNDER PRESSURE Bitcoin near $77K as the Binance hack adds to a broader tech selloff. 🔴 $COIN: -12.5% 🔴 $MSTR: -10.3% 🔴 $CRCL: -9.1% 🔴 $HOOD: -8.4% Crypto-linked equities are taking a much bigger hit than Bitcoin itself.

🚨 MARKET OPEN | TECH SELLOFF Nasdaq -2.2% shortly after the bell. 🔴 $INTC: Weak Q4 guidance 🔴 $RDDT: User growth concerns 🔴 $AMZN: AI spending and cash flow pressure Three earnings reactions, one message: Wall Street wants returns, not just growth.

📊 OCT 30 | PREMARKET EARNINGS RECAP A packed Friday across energy, healthcare and industrials. $XOM $CVX $ABBV $REGN and $GD deliver strong results, while $CCJ and $LYB fall short of expectations. 4 slides. Revenue, EPS, beats & misses. 👇

AbbVie, $ABBV, Q3-26. Skyrizi and Rinvoq power another guidance hike. 🟢 Revenue: $17.40B | +10.3% YoY 🟢 Adj. EPS: $3.82 | vs. $3.73 est. 💊 Skyrizi + Rinvoq: $8.48B | +23% YoY 📈 FY26 EPS guidance raised to $13.95–$13.99.

Canadian National Railway, $CNI, Q3-26. Strong freight demand and pricing fueled double-digit growth. 🟢 Revenue: C$4.77B | +15% YoY 🟢 Adj. EPS: C$2.16 | +18% YoY 🚆 Freight volumes (RTMs): +4% YoY *All financial figures in Canadian dollars (CAD).

Dominion Energy, $D, Q3-26. A huge revenue beat, but no guidance hike. 🟢 Revenue: $5.62B vs $4.91B est. 🟢 Adj. EPS: $1.28 vs $1.20 est. ⚡ Virginia earnings: $862M, +27% YoY 🎯 FY26 EPS: $3.45–$3.69; expects upper half.

General Dynamics, $GD, Q3-26. Massive submarine orders send backlog past $220B. 🟢 Revenue: $14.57B vs. $13.73B est. 🟢 Diluted EPS: $4.49 vs. $4.12 est. ⚓ Orders: $98.8B | 6.8x book-to-bill 📈 Backlog: $220.3B | +101% YoY

Colgate-Palmolive, $CL, Q3-26. Earnings outlook raised despite North American weakness. 🟢 Revenue: $5.37B vs. $5.34B est. 🟢 Adj. EPS: $0.97 vs. $0.93 est. 📈 FY26 EPS growth outlook raised to 5–7%. 🔴 North America organic sales: -1.6% YoY.

Regeneron, $REGN, Q3-26. Sanofi profit-sharing fueled a massive earnings beat. 🟢 Revenue: $5.12B vs $4.56B est. 🟢 Adj. EPS: $20.07 vs $16.19 est. 🤝 Sanofi revenue: $2.72B, +68% YoY 💰 Another $1B from Sanofi to hit Q4 revenue.

Cameco, $CCJ, Q3-26. Higher uranium prices couldn't offset falling output and rising costs. 🔴 Revenue: $619M | vs $754M est. 🔴 Adj. EPS: ~$0.00 | vs $0.07 YoY ⛏️ Uranium production: -20% YoY 📉 Adj. EBITDA: $267M | -14% YoY *All financial figures in Canadian dollars.

ExxonMobil, $XOM, Q3-26. Refining profits more than doubled, and another $20B buyback is planned. 🟢 Revenue: $113.2B vs $104.9B est. 🟢 Adj. EPS: $4.23 vs $4.12 est. ⛽ Energy Products profit: $9.1B vs $4.1B QoQ 💰 2027 buybacks: $20B

Chevron, $CVX, Q3-26. Higher oil prices lifted profits, but refining stole the show. 🟢 Revenue: $65.24B | vs. $61.11B est. 🟢 Adj. EPS: $5.28 | vs. $4.88 est. 🏭 Downstream earnings: $4.93B | 4.3x YoY 💵 Free cash flow: $12.0B | +143% YoY

BP, $BP, Q3-26. Refining profits surged, and BP hit its debt target a year early. 🟢 Revenue: $68.40B | +41.3% YoY 🟢 Adj. EPS: $3.26 | vs. $2.62 est. 💰 Underlying profit: $8.46B | vs. $7.33B est. 📉 Net debt: $13.87B | down $8.4B QoQ

AstraZeneca, $AZN, Q3-26. Cancer drugs drive a double beat as a $2B restructuring begins. 🟢 Revenue: $16.21B vs $15.99B est. 🟢 Adj. EPS: $2.79 vs $2.59 est. 🧬 Oncology: +16% CER (9M) 🏗️ Restructuring: Up to $2B in costs, targeting $1.5B annual savings.